top of page
NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression
About the study
NCT Trial Number
The drug being studied
NeuroRx, Inc.|Target Health Inc.
Trial Start Date
About the participants
18 Years to 65 Years
Primary condition of volunteers accepted
Accepts healthy volunteers?
This study will explore treatment response of a ketamine infusion, NRX-100, in achieving rapid reduction in symptoms of depression and suicidal ideation in patients with Severe Bipolar Depression and Acute Suicidal Ideation or Behavior within 24 hours of administration.
United States, Florida
Research Centers of America Recruiting
Hollywood, Florida, United States, 33024
Contact: Peter Ventre, MD
United States, Texas
JP Smith Hospital
Fort Worth, Texas, United States, 76104
Contact: Alan Podawiltz, DO, MS, FAPA
Contact: Cindy Claassen, PhD
bottom of page